Gautam Sajeev
Boston
Education
Sc.D., epidemiology, Harvard T.H. Chan School of Public Health; M.S., biostatistics, University of Toronto; B.S., mathematics and statistical science, University College London
Summary of Experience
Dr. Sajeev’s expertise is in the application of statistical and epidemiologic methods to the design and analysis of clinical and real-world studies of health care data. He also has a wide range of experience in health economics and outcomes research (HEOR), including comparative effectiveness studies; indirect treatment comparisons; systematic and targeted literature reviews; and chart review, survey, and patient preference studies. Dr. Sajeev’s research has covered a variety of therapeutic areas, including neuromuscular disorders, rare genetic diseases, hematology, neurology, and psychiatry. In his work on Duchenne muscular dystrophy, he has collaborated with academic experts, biotech and pharmaceutical companies, and other stakeholders on research to inform drug development and clinical trial design. Dr. Sajeev’s research has been used in submissions to clinical regulators and health care payers, presented at numerous conferences, and published in peer-reviewed journals such as Neurology, Circulation, Epidemiology, The American Journal of Psychiatry, and Movement Disorders.
Selected Publishing
-
DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-Institution Meta-Analysis with Implications for Clinical Trials
Neurology, 2023
2023Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I, Ward SJ, McDonald C, Goemans N, Niks EH, Wong B, Servais L, Straub V, Guglieri M, de Groot IJM, Chesshyre M, Tian C, Manzur AY, Mercuri E, Aartsma-Rus A
-
Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine(Ratio), and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy
Neurology, 2023
2023van de Velde NM, Koeks Z, Signorelli M, Verwey N, Overzier M, Bakker JA, Sajeev G, Signorovitch J, Ricotti V, Verschuuren J, Brown K, Spitali P, Niks EH
-
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood
Transplantation and Cellular Therapy, 2022
2022Lin C, Sajeev G, Stiff PJ, Brunstein CG, Cutler C, Sanz G, Lindemans CA, Rezvani AR, Hanna R, Koh LP, Maziarz RT, Hwang WYK, Song Y, Liu Q, Manghani R, Sivaraman S, Signorovitch J, Horwitz ME, Sung AD
-
Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
Expert Opinion on Pharmacotherapy, 2021
2021Gorevic P, Franklin J, Chen J, Sajeev G, Wang JCH, Lin H
-
Primary Hyperoxaluria Type 1 Disease Manifestations and Healthcare Utilization: A Multi-Country, Online, Chart Review Study
Frontiers in Medicine, 2021
2021Wang X, Danese D, Brown T, Baldwin J, Sajeev G, Cook EE, Wang Y, Xu C, Hongbo Yang H, Moritz ML
-
Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration
PLOS One, 2020
2020Goemans N, Wong B, Van den Hauwe M, Signorovitch J, Sajeev G, Cox D, Landry J, Jenkins M, Dieye I, Yao Z, Hossain I, Ward SJ, Collaborative Trajectory Analysis Project (cTAP)
-
Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
Neurology, 2020
2020Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandenborne K, Miller D, Ward SJ, Mercuri E, investigators from PRO-DMD-01 study, CINRG DNHS, ImagingDMD, and The DMD Italian Group
-
Suitability of natural history data for external controls in Duchenne muscular dystrophy
Neurology, 2020
2020Goemans N, Signorovitch J, Sajeev G, Yao Z, Gordish-Dressman H, McDonald CM, Vandenborne K, Miller D, Ward SJ, Mercuri E
-
Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: a meta-analysis of disease progression rates in recent multicenter clinical trials
Muscle & Nerve, 2020
2020McDonald CM, Sajeev G, Yao Z, McDonnell E, Elfring G, Souza M, Peltz SW, Darras BT, Shieh PB, Cox DA, Landry J, Signorovitch J, ACT DMD Study Group and the Tadalafil DMD Study Group
-
Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy
PLOS One, September 3, 2019
2019Muntoni F, Domingos J, Manzur AY, Mayhew A, Guglieri M, The UK NorthStar Network, Sajeev G, Signorovitch J, Ward SJ
-
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
Advances in Therapy, 2019
2019Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D
-
Validation of an ambient measurement system (AMS) for physical activities in a paediatric population
Journal of Medical Engineering & Technology, 2019
2019Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW
-
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
Circulation. 2018 Oct 2;138(14):1387-1398
2018Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F1, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivotto I
-
Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator
Journal of Stroke and Cerebrovascular Diseases. Sep 2017;26(9):1996-2003
2017Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ
News
-
December 6, 2023
-
December 1, 2023
-
December 7, 2022
-
July 19, 2022